Leerink Partnrs Increases Earnings Estimates for REGENXBIO

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2027 earnings per share (EPS) estimates for shares of REGENXBIO in a report issued on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($1.25) per share for the year, up from their previous estimate of ($1.87). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's FY2028 earnings at $1.10 EPS.

A number of other research analysts have also weighed in on the stock. Barclays cut their target price on shares of REGENXBIO from $55.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, August 5th. Morgan Stanley restated an "overweight" rating and set a $22.00 target price on shares of REGENXBIO in a research note on Friday, November 15th. Raymond James reaffirmed an "outperform" rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. HC Wainwright increased their price objective on REGENXBIO from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Finally, StockNews.com raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, September 20th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.64.

REGENXBIO Trading Up 0.7 %

Shares of REGENXBIO stock opened at $9.63 on Thursday. The firm has a fifty day simple moving average of $10.37 and a 200-day simple moving average of $12.14. The stock has a market capitalization of $477.07 million, a price-to-earnings ratio of -1.91 and a beta of 1.23. REGENXBIO has a 1-year low of $8.53 and a 1-year high of $28.80.

Insider Activity

In other news, Director Argeris N. Karabelas sold 10,000 shares of the business's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the sale, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 46.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 13.13% of the company's stock.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds have recently made changes to their positions in RGNX. FMR LLC grew its stake in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,656 shares during the last quarter. nVerses Capital LLC increased its holdings in REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 2,200 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company's stock valued at $100,000 after purchasing an additional 3,720 shares during the last quarter. Diversified Trust Co acquired a new position in REGENXBIO in the second quarter worth $121,000. Finally, Arizona State Retirement System grew its holdings in shares of REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company's stock worth $137,000 after purchasing an additional 1,997 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.